呼吸器ウイルス・ワクチンの世界市場

呼吸器ウイルス・ワクチンの世界市場は2030年までに115億米ドルに達する

2024年に85億米ドルと推定される呼吸器ウイルス・ワクチンの世界市場は、分析期間2024-2030年にCAGR 5.1％で成長し、2030年には115億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである不活化／キルドワクチンは、CAGR 4.5%を記録し、分析期間終了時には71億米ドルに達すると予測されます。弱毒化／生ワクチンの成長率はCAGR 5.8%と推定されます。

米国市場は23億米ドルと推定、中国はCAGR 8.0％で成長予測

米国の呼吸器ウイルス・ワクチン市場は2024年に23億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.0%で推移し、2030年には市場規模が23億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.0％と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界の呼吸器ウイルス・ワクチン市場- 主要動向と促進要因のまとめ

パンデミック後に呼吸器系ワクチンへの注目度が世界的に高まったのはなぜか？

パンデミック後、呼吸器ウイルス・ワクチンへの注目は世界的に高まり、公衆衛生の優先順位とワクチンイノベーションの課題が再構築されました。政府、ヘルスケア組織、製薬大手は、SARS-CoV-2だけでなく、インフルエンザ、RSV（呼吸器合胞体ウイルス）、アデノウイルスなどの長年にわたる呼吸器病原体にも対処できる、より広範なスペクトルを持つワクチンの開発に注力する姿勢を加速させています。パンデミックによって、世界の人々、特に高齢者や免疫不全者が季節性・新興の呼吸器系ウイルスに対して脆弱であることが露呈し、ワクチン対策が改めて急務となりました。このような意識の高まりにより、呼吸器疾患の予防を目的としたワクチン接種率の向上、資金援助、官民連携が行われるようになりました。また、1回の接種で複数の呼吸器系ウイルスを予防できる混合ワクチンを開発する企業も増えており、利便性とコンプライアンスが向上しています。これと並行して、医療機関はコールドチェーン・インフラを整備し、十分なサービスを受けていない地域でも予防接種が受けられるよう、予防接種プログラムに投資しています。毎年のブースター・キャンペーン、迅速対応ワクチン・プラットフォーム、世界の疾病サーベイランスの重視は、この分野の新たな勢いをさらに際立たせています。さらに、COVID-19ワクチンの展開により、mRNAやウイルスベクター技術に対する社会的信頼が高まり、従来のインフルエンザ予防接種にとどまらない呼吸器系ワクチンへの応用の道が開かれました。鳥インフルエンザの亜種や人獣共通感染症といった新たな脅威が迫り来る中、呼吸器系ワクチンは今や世界のパンデミック対策戦略の中心的なツールとみなされています。

ワクチン開発の限界を押し広げる新技術とは？

技術革新は、ワクチン開発に大きな変化をもたらしています。mRNAベースのワクチンは、迅速な開発サイクル、高い有効性、容易な再プログラミングが可能であり、ウイルスの変異に対応するのに理想的です。ウイルスベクタープラットフォームや組換えタンパク質サブユニットワクチンも、副作用を抑えながら強力な免疫反応を刺激できることから、開発が進んでいます。経鼻ワクチンは、呼吸器病原体の侵入を阻止するために重要な粘膜免疫を刺激する能力により、人気を集めています。AIとバイオインフォマティクスツールは、抗原ドリフトを予測し、エピトープ選択を最適化することで、ワクチンデザインに革命をもたらしています。さらに、脂質ナノ粒子送達システムは、ワクチンの安定性と細胞への取り込みを改善し、低用量でも免疫応答を高めています。凍結乾燥製剤を用いたコールドチェーン非依存型ワクチンは、遠隔地や低所得地域における物流の課題を克服するために開発されています。T細胞応答を高めるアジュバントが次世代ワクチンに統合され、特に高齢者に対し、より長期の予防効果を提供できるようになりつつあります。合成生物学とCRISPRを用いた抗原マッピングの応用も、高度に標的化された広域スペクトル呼吸器ワクチンを設計するためのフロンティアとして浮上しています。これらの進歩は、単に有効性を向上させるだけでなく、新たな呼吸器系の脅威に直面した際に、いかに迅速にワクチンを開発・展開できるかを再定義しています。

どのような患者集団と使用事例が最も需要を牽引しているか？

呼吸器ウイルス・ワクチンの需要を牽引しているのは、高リスクかつ高被曝の患者集団です。インフルエンザやRSV感染による罹患率が最も高い高齢者は、継続的なワクチン接種キャンペーンやブースターワクチン接種キャンペーンにとって重要なセグメントです。乳幼児は、特に小児医療へのアクセスが限られている地域では、依然として脆弱な層であり、RSVワクチンやアデノウイルスワクチンの普及を促進しています。ヘルスケア従事者や最前線で対応する人々は、労働安全の義務化によって、ワクチン接種を受ける集団が増加しています。移植を受けた患者や化学療法を受けている患者を含む免疫不全者も、呼吸器感染症にかかりやすいため、優先的に接種を受ける必要があります。各国が健康入国規制を強化し、国境を越えた移動にワクチンを推奨しているため、旅行・観光産業はワクチン需要にさらに影響を与えています。COPDや喘息などの慢性呼吸器疾患患者は、入院や疾病負担を軽減するため、国の予防接種プログラムが積極的に対象としています。教育機関や職場では、欠勤や地域社会への蔓延を最小限に抑えるため、呼吸器系ワクチンの接種活動が行われています。小児科での使用事例は、接種範囲を広げつつ注射回数を減らす混合ワクチンによって拡大しています。さらに、軍隊や防衛隊は、近距離での生活環境のため、呼吸器系ウイルスに対する予防接種を日常的に行っています。これらすべてのセグメントにおいて、呼吸器感染症は繰り返し発生するため、継続的な需要が確保され、生産の拡張性と市場の持続性が促進されています。

呼吸器ウイルス・ワクチン市場の急成長の背景は？

世界の呼吸器ウイルス・ワクチン市場の成長は、技術の進歩、人口動向、ヘルスケア行動の進化に関連するいくつかの要因によってもたらされています。呼吸器系アウトブレイクの頻度と重症度の増加（季節性と緊急性の両方）により、信頼性の高いワクチンソリューションに対する長期的な需要が生じています。COVID-19ワクチンの急速な開発と成功は、mRNAや組み換えベクターのような次世代プラットフォームへの投資を促進し、より迅速な技術革新と市場準備を可能にしています。特に新興経済諸国では世界の高齢化が進んでおり、高齢者向け予防接種プログラムの一環としてインフルエンザワクチンやRSVワクチンの需要が持続しています。小児科の予防接種スケジュールが拡大されたことで、公的・民間ヘルスケアセクターの双方で年間を通じて安定した需要が生まれています。都市化、人口密度、世界の流動性により、ウイルス感染拡大のリスクが高まっており、各国政府は集団予防接種戦略の導入を促しています。パンデミック後の公衆衛生意識の高まりは、ワクチン受容性を向上させ、接種へのためらいを減らし、接種率の上昇を促しています。多国籍製薬会社は、規制当局の迅速な対応と国際的な資金援助により、生産能力を拡大しています。呼吸器系ワクチンを毎年接種するブースターが増加傾向にあることも、ワクチン市場を季節性から継続的な需要サイクルへと変化させています。普遍的インフルエンザワクチンの開発、世界的流行への備えの枠組み、日常診療における呼吸器系ワクチンの統合といった戦略的イニシアチブは、市場の上昇基調をさらに強めています。

セグメント

タイプ（不活化／キルド,活性化,遺伝子組換え）;効能（インフルエンザ,麻疹,流行性耳下腺炎・風疹,コロナウイルス）;投与経路（筋肉内,鼻腔内,皮下）;エンドユーザー（医院,病院,クリニック,薬局／店舗,その他のエンドユーザー）

調査対象企業の例（全36件）

• Alphavax, Inc.
• AstraZeneca plc
• Bavarian Nordic A/S
• BioNTech SE
• Codagenix Inc.
• CureVac N.V.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc（GSK）
• Intravacc B.V.
• Johnson & Johnson
• Medicago Inc.
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Shionogi & Co., Ltd.
• Sinovac Biotech Ltd.
• SOBI（Swedish Orphan Biovitrum AB）

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Respiratory Virus Vaccines Market to Reach US$11.5 Billion by 2030

The global market for Respiratory Virus Vaccines estimated at US$8.5 Billion in the year 2024, is expected to reach US$11.5 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Inactivated / Killed Vaccines, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Live-Attenuated Vaccines segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.0% CAGR

The Respiratory Virus Vaccines market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Respiratory Virus Vaccines Market - Key Trends & Drivers Summarized

Why Has the Global Focus on Respiratory Vaccines Intensified Post-Pandemic?

The spotlight on respiratory virus vaccines has intensified globally in the aftermath of the COVID-19 pandemic, reshaping public health priorities and vaccine innovation agendas. Governments, healthcare organizations, and pharmaceutical giants have accelerated their focus on developing broader-spectrum vaccines capable of tackling not just SARS-CoV-2 but also long-standing respiratory pathogens such as influenza, RSV (Respiratory Syncytial Virus), and adenoviruses. The pandemic exposed the vulnerabilities of global populations-particularly the elderly and immunocompromised-to seasonal and emerging respiratory viruses, prompting renewed urgency in vaccine preparedness. This surge in awareness has led to increased vaccination coverage, funding, and public-private partnerships aimed at respiratory disease prevention. A growing number of vaccine developers are also exploring combination vaccines that offer protection against multiple respiratory viruses in a single dose, improving convenience and compliance. In parallel, health systems are investing in better cold chain infrastructure and immunization programs to reach underserved communities. The emphasis on annual booster campaigns, rapid-response vaccine platforms, and global disease surveillance further underscores the sector’s newfound momentum. Moreover, the COVID-19 vaccine rollout has increased public trust in mRNA and viral vector technologies, opening doors to respiratory vaccine applications beyond traditional flu shots. With emerging threats such as avian flu variants and zoonotic diseases looming, respiratory vaccines are now viewed as central tools in global pandemic preparedness strategies.

What New Technologies Are Pushing the Boundaries of Vaccine Development?

Technological innovation is driving a major transformation in the respiratory virus vaccines landscape. The adoption of mRNA vaccine platforms, pioneered during the COVID-19 pandemic, is now being extended to target other respiratory viruses such as influenza and RSV. mRNA-based vaccines offer rapid development cycles, high efficacy, and easy reprogramming, making them ideal for responding to viral mutations. Viral vector platforms and recombinant protein subunit vaccines are also being advanced for their ability to stimulate strong immune responses with reduced side effects. Intranasal vaccines are gaining traction due to their ability to stimulate mucosal immunity-important for blocking respiratory pathogens at the entry point. AI and bioinformatics tools are revolutionizing vaccine design by predicting antigenic drift and optimizing epitope selection. Additionally, lipid nanoparticle delivery systems are improving vaccine stability and cellular uptake, enhancing immune responses even at lower doses. Cold-chain-independent vaccines using lyophilized formulations are being developed to overcome logistical challenges in remote and low-income regions. Adjuvants that boost T-cell responses are being integrated into next-gen vaccines to offer longer-lasting protection, especially for older adults. The application of synthetic biology and CRISPR-based antigen mapping is also emerging as a frontier for designing highly targeted, broad-spectrum respiratory vaccines. These advancements are not just improving efficacy but are redefining how quickly vaccines can be developed and deployed in the face of new respiratory threats.

Which Patient Populations and Use Cases Are Driving the Most Demand?

The primary drivers of demand for respiratory virus vaccines stem from high-risk and high-exposure population groups. Elderly individuals, who suffer the highest morbidity from influenza and RSV infections, represent a critical segment for ongoing and booster vaccination campaigns. Infants and young children, especially in regions with limited access to pediatric healthcare, remain another vulnerable demographic, driving adoption of RSV and adenovirus vaccines. Healthcare workers and frontline responders form a growing vaccination cohort, supported by occupational safety mandates. Immunocompromised individuals-including transplant recipients and patients undergoing chemotherapy-are also prioritized due to their heightened susceptibility to respiratory infections. Travel and tourism industries are further influencing vaccine demand as countries tighten health entry regulations and recommend vaccines for cross-border movement. Chronic respiratory disease sufferers, such as those with COPD or asthma, are being actively targeted by national immunization programs to reduce hospitalization and disease burden. Educational institutions and workplaces are adopting respiratory vaccination drives to minimize absenteeism and community spread. The pediatric use case is expanding with combination vaccines that reduce the number of injections while broadening coverage. Additionally, military and defense forces are routinely immunized against respiratory viruses due to close-quarter living conditions. Across all these segments, the recurring nature of respiratory infections is ensuring continuous demand, fueling production scalability and market sustainability.

What’s Behind the Surging Growth in the Respiratory Virus Vaccines Market?

The growth in the global respiratory virus vaccines market is driven by several factors related to technological progress, demographic trends, and evolving healthcare behaviors. The increasing frequency and severity of respiratory outbreaks-both seasonal and emergent-are creating long-term demand for reliable vaccine solutions. The rapid development and success of COVID-19 vaccines have catalyzed investment in next-gen platforms like mRNA and recombinant vectors, enabling faster innovation and market readiness. An aging global population, particularly in developed economies, is contributing to sustained demand for influenza and RSV vaccines as part of elderly immunization programs. Expanded pediatric immunization schedules are creating consistent year-round demand in both public and private healthcare sectors. Urbanization, population density, and global mobility are intensifying the risk of viral spread, prompting governments to adopt mass immunization strategies. Heightened public health awareness post-pandemic has improved vaccine acceptance, reducing hesitancy and driving higher uptake. Multinational pharmaceutical firms are expanding production capacities, aided by regulatory fast-tracking and international funding. The growing trend of annual respiratory vaccine boosters is also transforming vaccine markets from seasonal to continuous demand cycles. Strategic initiatives like universal flu vaccine development, global pandemic preparedness frameworks, and the integration of respiratory vaccines in routine care are further reinforcing the market’s upward trajectory.

SCOPE OF STUDY:

The report analyzes the Respiratory Virus Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Inactivated / Killed, Live-Attenuated, Recombinant); Indication (Influenza, Measles, Mumps & Rubella, Coronavirus); Administration Route (Intramuscular, Intranasal, Subcutaneous); End-Use (Physician Offices, Hospitals, Clinics, Pharmacies / Stores, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Alphavax, Inc.
• AstraZeneca plc
• Bavarian Nordic A/S
• BioNTech SE
• Codagenix Inc.
• CureVac N.V.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc (GSK)
• Intravacc B.V.
• Johnson & Johnson
• Medicago Inc.
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Shionogi & Co., Ltd.
• Sinovac Biotech Ltd.
• SOBI (Swedish Orphan Biovitrum AB)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Respiratory Virus Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Influenza, RSV, and Emerging Respiratory Pathogens Propels Vaccine Demand
  • Expansion of mRNA and Vector-Based Platforms Accelerates Development of Next-Gen Respiratory Vaccines
  • Government Procurement Programs and Pandemic Preparedness Policies Sustain Market Growth
  • Increased Focus on Combination Vaccines (COVID-19 + Influenza) Drives R&D and Product Pipeline
  • Public Health Awareness Campaigns and Immunization Drives Enhance Vaccine Uptake
  • Technological Innovations in Nasal and Inhaled Vaccine Delivery Boost Market Accessibility
  • Cold Chain Logistics Improvements Strengthen Global Distribution Capabilities
  • Private Sector Investment and Public-Private Partnerships Accelerate Regulatory Approvals
  • Seasonal Demand Patterns and Aging Populations Create Recurring Market Cycles
  • Vaccine Hesitancy and Misinformation Pose Challenges for Universal Immunization Coverage
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Respiratory Virus Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Respiratory Virus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Respiratory Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated / Killed by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Inactivated / Killed by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Inactivated / Killed by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Live-Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Live-Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Live-Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Physician Offices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Physician Offices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Physician Offices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharmacies / Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharmacies / Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pharmacies / Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Measles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Measles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Measles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Mumps & Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Mumps & Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Mumps & Rubella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Coronavirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Coronavirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Coronavirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• JAPAN
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• CHINA
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• EUROPE
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Respiratory Virus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Respiratory Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• FRANCE
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• GERMANY
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Respiratory Virus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• INDIA
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Respiratory Virus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Respiratory Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Respiratory Virus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Respiratory Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030
• AFRICA
  • Respiratory Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Respiratory Virus Vaccines by Type - Inactivated / Killed, Live-Attenuated and Recombinant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Respiratory Virus Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated / Killed, Live-Attenuated and Recombinant for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Respiratory Virus Vaccines by Administration Route - Subcutaneous, Intramuscular and Intranasal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Respiratory Virus Vaccines by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular and Intranasal for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Respiratory Virus Vaccines by End-Use - Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Respiratory Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Physician Offices, Hospitals, Clinics, Pharmacies / Stores and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Respiratory Virus Vaccines by Indication - Influenza, Measles, Mumps & Rubella and Coronavirus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Respiratory Virus Vaccines by Indication - Percentage Breakdown of Value Sales for Influenza, Measles, Mumps & Rubella and Coronavirus for the Years 2015, 2025 & 2030

IV. COMPETITION